Prescription medicine
Latanoprost and netarsudil Brand names: Rocklatan
Latanoprost and netarsudil (Rocklatan) is a prescription medicine with an FDA approval on record since 2019. No generic is listed; pharmacies paid $139.40 per mL (Rocklatan 0.02%-0.005% eye drp) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the latanoprost and netarsudil FDA label on DailyMed (effective August 27, 2026, Alcon Laboratories, Inc.); the NDA 208259 record on Drugs@FDA; every latanoprost and netarsudil label on DailyMed.
Highlights of the record
FDA label of August 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageINDICATIONS AND USAGE ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Forms and strengths
- 0.2 mg/ml / 0.05 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- March 12, 2019 Rocklatan, Alcon Labs Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- March 14, 2034 Rocklatan solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $139.40 per mL Rocklatan 0.02%-0.005% eye drp
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 939 through July 30, 2026
What is latanoprost and netarsudil used for?
From the label: indications and usageINDICATIONS AND USAGE ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ROCKLATAN ® is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Conditions named in the indications of latanoprost and netarsudil's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Prostaglandin Analog and Rho Kinase Inhibitor.
Source: FDA drug label (Rocklatan), Alcon Laboratories, Inc., effective August 27, 2026 (SPL set b1d71f41-be06-4a08-94d4-e352198f09c2), via openFDA; the full label on DailyMed
Is there a generic for latanoprost and netarsudil (Rocklatan)?
No generic latanoprost and netarsudil is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 17 patents for Rocklatan solution/drops: the compound patent runs to March 14, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2034 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for latanoprost and netarsudil (Rocklatan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $139.40 per mL (Rocklatan 0.02%-0.005% eye drp), up 3% from $135.57 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Rocklatan 0.02%-0.005% eye drp (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Rocklatan 0.02%-0.005% eye drp | Brand | $139.40 per mL | n/a | +3% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for latanoprost and netarsudil?
The FDA Adverse Event Reporting System holds 939 reports that list latanoprost and netarsudil among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 44 are coded as a death and 52 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other prostaglandin analogs
- the pharmacologic class, with prices and generics
- Latanoprost and netarsudil side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other